Table 1.
Characteristic | N (%) |
---|---|
Demographics | |
Age | |
• 0–19 years | 3 (3%) |
• 20–39 years | 6 (6%) |
• 40–59 years | 28 (27%) |
• 60–79 years | 51 (50%) |
• 80+ years | 15 (15%) |
Sex | |
• Female | 49 (48%) |
• Male | 54 (52%) |
Possible indication for IGIV use* | |
Autoimmune/inflammatory condition | 68 (66%) |
Immune deficiency | 39 (38%) |
Infection | 16 (16%) |
Bone marrow or hematopoietic stem cell transplant | 8 (8%) |
Other indication | 26 (25%) |
Major cardiovascular risk factors* | |
Myocardial infarction | 23 (22%) |
Angina | 40 (39%) |
Atrial fibrillation or flutter | 15 (15%) |
Ischemic stroke | 6 (6%) |
Peripheral vascular disease | 18 (17%) |
Hypertension, uncomplicated | 58 (56%) |
Hypertension, complicated (i.e., with end-organ damage) | 20 (19%) |
Diabetes mellitus | 27 (26%) |
Data Partner type | |
Insurer/claims-based | 83 (81%) |
Integrated healthcare delivery system | 20 (19%) |
Possible indications and cardiovascular risk factors were assessed using diagnoses and procedures recorded in administrative data during the 183 days prior to the patient’s IGIV treatment date. The indication indicator variables are not mutually exclusive, so indication percentages may sum to greater than 100%.